Apellis Pharmaceuticals (APLS) Insider Trading & Ownership $27.57 -0.48 (-1.71%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$27.57 +0.00 (+0.00%) As of 08/29/2025 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Apellis Pharmaceuticals (NASDAQ:APLS) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage6.50%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)9Amount OfInsider Selling(Last 12 Months)$13.19M Get APLS Insider Trade Alerts Want to know when executives and insiders are buying or selling Apellis Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. APLS Insider Buying and Selling by Quarter Apellis Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/28/2025Cedric FrancoisCEOSell49,963$28.39$1,418,449.57 8/27/2025Cedric FrancoisCEOSell175,037$28.19$4,934,293.03 8/18/2025David O WatsonGeneral CounselSell5,000$27.80$139,000.00 7/17/2025Cedric FrancoisCEOSell19,725$20.21$398,642.25 7/16/2025David O WatsonGeneral CounselSell5,000$19.55$97,750.00 7/15/2025Cedric FrancoisCEOSell1,900$20.09$38,171.00 7/14/2025Cedric FrancoisCEOSell137,465$20.19$2,775,418.35 6/16/2025David O WatsonGeneral CounselSell5,000$18.77$93,850.00 3/17/2025James George ChopasCAOSell183$24.82$4,542.06 3/5/2025David O WatsonGeneral CounselSell5,569$25.10$139,781.90 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 2/11/2025Mark Jeffrey DelongInsiderSell363$28.54$10,360.02 1/29/2025Cedric FrancoisCEOSell2,824$29.52$83,364.48 1/29/2025David O WatsonGeneral CounselSell695$29.52$20,516.40 1/29/2025Nur NicholsonInsiderSell825$29.52$24,354.00 1/29/2025Timothy Eugene SullivanCFOSell546$29.52$16,117.92 1/22/2025Cedric FrancoisCEOSell13,551$30.43$412,356.93 1/22/2025David O WatsonGeneral CounselSell3,323$30.43$101,118.89 1/22/2025James George ChopasCAOSell1,096$30.43$33,351.28 1/22/2025Nur NicholsonInsiderSell3,948$30.43$120,137.64 1/22/2025Timothy Eugene SullivanCFOSell3,088$30.43$93,967.84 1/17/2025Cedric FrancoisCEOSell6,007$29.96$179,969.72 1/17/2025David O WatsonGeneral CounselSell2,201$29.96$65,941.96 1/17/2025James George ChopasCAOSell715$29.96$21,421.40 1/17/2025Nur NicholsonInsiderSell2,145$29.96$64,264.20 1/17/2025Timothy Eugene SullivanCFOSell1,730$29.96$51,830.80 1/13/2025Cedric FrancoisCEOSell6,247$28.70$179,288.90 1/13/2025David O WatsonGeneral CounselSell4,965$28.70$142,495.50 1/13/2025James George ChopasCAOSell783$28.70$22,472.10 1/13/2025Jeffrey EiseleInsiderSell264$28.70$7,576.80 1/13/2025Timothy Eugene SullivanCFOSell2,170$28.70$62,279.00 1/6/2025Caroline BaumalInsiderSell2,816$33.81$95,208.96 12/23/2024Jeffrey EiseleInsiderSell63$33.09$2,084.67 9/16/2024A. Sinclair DunlopDirectorSell37,000$36.23$1,340,510.00 (Data available from 1/1/2013 forward) APLS Insider Trading Activity - Frequently Asked Questions Who is on Apellis Pharmaceuticals' Insider Roster? The list of insiders at Apellis Pharmaceuticals includes A. Sinclair Dunlop, Adam J Townsend, Alec Machiels, Caroline Baumal, Cedric Francois, David O Watson, Federico Grossi, James George Chopas, Jeffrey Eisele, Karen Lewis, Lukas Scheibler, Mark Jeffrey Delong, Nur Nicholson, Pascal Deschatelets, and Timothy Eugene Sullivan. Learn more on insiders at APLS. What percentage of Apellis Pharmaceuticals stock is owned by insiders? 6.50% of Apellis Pharmaceuticals stock is owned by insiders. Learn more on APLS's insider holdings. Which Apellis Pharmaceuticals insiders have been selling company stock? The following insiders have sold APLS shares in the last 24 months: A. Sinclair Dunlop ($3,860,569.58), Adam J Townsend ($299,644.96), Alec Machiels ($233,225.00), Caroline Baumal ($260,406.51), Cedric Francois ($34,802,349.30), David O Watson ($1,690,211.41), James George Chopas ($247,659.33), Jeffrey Eisele ($42,858.73), Lukas Scheibler ($600,000.00), Mark Jeffrey Delong ($580,440.96), Nur Nicholson ($1,809,030.44), Pascal Deschatelets ($8,651,477.64), and Timothy Eugene Sullivan ($1,315,269.78). How much insider selling is happening at Apellis Pharmaceuticals? Insiders have sold a total of 1,274,281 Apellis Pharmaceuticals shares in the last 24 months for a total of $54,393,143.64 sold. Apellis Pharmaceuticals Key ExecutivesDr. Cedric Francois M.D. (Age 52)Ph.D., Co-Founder, President, CEO & Director Compensation: $1.44MMr. Alec Machiels J.D. (Age 51)MBA, Co-Founder & Director Compensation: $90.62kMr. Timothy E. Sullivan (Age 53)CFO & Treasurer Compensation: $793.43kMr. Adam J. Townsend (Age 46)Chief Operating Officer Compensation: $770.44kMr. David O. Watson Esq. (Age 51)J.D., General Counsel Compensation: $764.37k4 recent tradesDr. Caroline R. Baumal M.D. (Age 56)Chief Medical Officer Compensation: $1.01MDr. Pascal Deschatelets Ph.D. (Age 54)Co-Founder & Chief Scientific Officer Compensation: $688.05kMr. James G. Chopas CPA (Age 57)VP, Corporate Controller & Chief Accounting Officer Ms. Meredith KayaSenior Vice President, Investor Relations & Strategic FinanceMs. Karen Lewis (Age 51)Chief People Officer More Insider Trading Tools from MarketBeat Related Companies Viatris Insider Transactions Moderna Insider Transactions BridgeBio Pharma Insider Transactions Verona Pharma PLC American Depositary Share Insider Transactions Elanco Animal Health Insider Transactions Blueprint Medicines Insider Transactions Roivant Sciences Insider Transactions Grifols Insider Transactions Revolution Medicines Insider Transactions Rhythm Pharmaceuticals Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Costco Faces Downgrades, Death Cross, Insider SellingReynolds Consumer Products Stock Price: Insiders Signal a BottomBuy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksInsiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift45 Stocks Insiders Are Selling That Analysts Say Buy This page (NASDAQ:APLS) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APLS Stock Alerts